BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 25388644)

  • 1. Rituximab use in patients with ANCA-associated vasculitis: clinical efficacy and impact on immunological parameters.
    Chocova Z; Hruskova Z; Mareckova H; Svobodova B; Duskova D; Bednarova V; Jancova E; Rysava R; Tesar V
    Clin Rheumatol; 2015 Jan; 34(1):107-15. PubMed ID: 25388644
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term follow-up of patients who received repeat-dose rituximab as maintenance therapy for ANCA-associated vasculitis.
    Alberici F; Smith RM; Jones RB; Roberts DM; Willcocks LC; Chaudhry A; Smith KG; Jayne DR
    Rheumatology (Oxford); 2015 Jul; 54(7):1153-60. PubMed ID: 25477054
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of rituximab on immunoglobulin concentrations and B cell numbers after cyclophosphamide treatment in patients with ANCA-associated vasculitides.
    Venhoff N; Effelsberg NM; Salzer U; Warnatz K; Peter HH; Lebrecht D; Schlesier M; Voll RE; Thiel J
    PLoS One; 2012; 7(5):e37626. PubMed ID: 22629432
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Highly Sensitive Flow Cytometric Detection of Residual B-Cells After Rituximab in Anti-Neutrophil Cytoplasmic Antibodies-Associated Vasculitis Patients.
    van Dam LS; Oskam JM; Kamerling SWA; Arends EJ; Bredewold OW; Berkowska MA; van Dongen JJM; Rabelink TJ; van Kooten C; Teng YKO
    Front Immunol; 2020; 11():566732. PubMed ID: 33384685
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rituximab for remission induction in elderly patients with ANCA-associated vasculitis.
    Timlin H; Lee SM; Manno RL; Seo P; Geetha D
    Semin Arthritis Rheum; 2015 Aug; 45(1):67-9. PubMed ID: 25796088
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rituximab versus cyclophosphamide for ANCA-associated vasculitis with renal involvement.
    Geetha D; Specks U; Stone JH; Merkel PA; Seo P; Spiera R; Langford CA; Hoffman GS; Kallenberg CG; St Clair EW; Fessler BJ; Ding L; Tchao NK; Ikle D; Jepson B; Brunetta P; Fervenza FC;
    J Am Soc Nephrol; 2015 Apr; 26(4):976-85. PubMed ID: 25381429
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of rituximab trials on the treatment of ANCA-associated vasculitis.
    Alberici F; Jayne DR
    Nephrol Dial Transplant; 2014 Jun; 29(6):1151-9. PubMed ID: 24126571
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of Serum Calprotectin (S100A8/A9) Level With Disease Relapse in Proteinase 3-Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
    Pepper RJ; Draibe JB; Caplin B; Fervenza FC; Hoffman GS; Kallenberg CG; Langford CA; Monach PA; Seo P; Spiera R; William St Clair E; Tchao NK; Stone JH; Specks U; Merkel PA; Salama AD;
    Arthritis Rheumatol; 2017 Jan; 69(1):185-193. PubMed ID: 27428710
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rituximab for anti-neutrophil cytoplasmic antibodies-associated vasculitis: experience of a single center and systematic review of non-randomized studies.
    Ayan G; Esatoglu SN; Hatemi G; Ugurlu S; Seyahi E; Melikoglu M; Fresko I; Ozdogan H; Yurdakul S; Hamuryudan V
    Rheumatol Int; 2018 Apr; 38(4):607-622. PubMed ID: 29322343
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rituximab in relapsing or refractory ANCA-associated vasculitis: a case series of 16 patients.
    Wendt M; Gunnarsson I; Bratt J; Bruchfeld A
    Scand J Rheumatol; 2012 Mar; 41(2):116-9. PubMed ID: 22118245
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibody-associated vasculitis.
    Smith RM; Jones RB; Guerry MJ; Laurino S; Catapano F; Chaudhry A; Smith KG; Jayne DR
    Arthritis Rheum; 2012 Nov; 64(11):3760-9. PubMed ID: 22729997
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reconstitution of the peripheral B lymphocyte compartment in patients with ANCA-associated vasculitides treated with rituximab for relapsing or refractory disease.
    Venhoff N; Niessen L; Kreuzaler M; Rolink AG; Hässler F; Rizzi M; Voll RE; Thiel J
    Autoimmunity; 2014 Sep; 47(6):401-8. PubMed ID: 24798501
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction treatment of ANCA-associated vasculitis with a single dose of rituximab.
    Turner-Stokes T; Sandhu E; Pepper RJ; Stolagiewicz NE; Ashley C; Dinneen D; Howie AJ; Salama AD; Burns A; Little MA
    Rheumatology (Oxford); 2014 Aug; 53(8):1395-403. PubMed ID: 24609057
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rituximab for treatment of severe renal disease in ANCA associated vasculitis.
    Geetha D; Hruskova Z; Segelmark M; Hogan J; Morgan MD; Cavero T; Eriksson P; Seo P; Manno RL; Dale J; Harper L; Tesar V; Jayne DR
    J Nephrol; 2016 Apr; 29(2):195-201. PubMed ID: 25986390
    [TBL] [Abstract][Full Text] [Related]  

  • 15. B cell repopulation kinetics after rituximab treatment in ANCA-associated vasculitides compared to rheumatoid arthritis, and connective tissue diseases: a longitudinal observational study on 120 patients.
    Thiel J; Rizzi M; Engesser M; Dufner AK; Troilo A; Lorenzetti R; Voll RE; Venhoff N
    Arthritis Res Ther; 2017 May; 19(1):101. PubMed ID: 28521808
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is B-cell depletion first choice in antineutrophil cytoplasmic antibody-associated vasculitis?
    Kallenberg CG
    Curr Opin Rheumatol; 2014 May; 26(3):292-8. PubMed ID: 24646946
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rituximab prescription patterns and efficacy in the induction treatment of ANCA-Associated Vasculitis in a Belgian multicenter cohort.
    Chasseur P; Blockmans D; von Frenckell C; Nicolas JB; Regniers C; Vandergheynst F
    Acta Clin Belg; 2020 Jun; 75(3):163-169. PubMed ID: 30767717
    [No Abstract]   [Full Text] [Related]  

  • 18. Moderator's view: Should all patients with ANCA-associated vasculitis be primarily treated with rituximab?
    Tesar V
    Nephrol Dial Transplant; 2015 Jul; 30(7):1088-90. PubMed ID: 25999373
    [TBL] [Abstract][Full Text] [Related]  

  • 19. B-cell therapy in antineutrophil cytoplasmic antibody-associated vasculitis.
    Kallenberg CG; Hauser T
    Nephrol Dial Transplant; 2015 Apr; 30 Suppl 1():i119-22. PubMed ID: 25753806
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single-dose rituximab for remission induction and maintenance therapy in ANCA-associated vasculitis: a retrospective analysis of 17 patients.
    Moog P; Probst M; Kuechle C; Hauser C; Heemann U; Thuermel K
    Scand J Rheumatol; 2014; 43(6):519-23. PubMed ID: 25179776
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.